Literature DB >> 7688352

Studies on 200 cases of early squamous cell carcinoma of the cervix.

A G Ostör1.   

Abstract

Two hundred cases of early squamous cell carcinoma of the cervix were studied, 109 with early stromal invasion (ESI) (FIGO stage Ia1) and 91 microcarcinomas (MCs) (stage Ia2). Nine percent of invasive foci arose from original (native) squamous epithelium, outside the transformation zone. What may have been "skip lesions" (see text) were seen in only two instances. Of the cases of ESI, 78% invaded to < or = 0.5 mm. Of the MCs, 65% invaded to < or = 3 mm, and > 50% measured < or = 50 mm3 in volume. Capillary-like space involvement (CLSI) was suspected in 32 cases (29%) of MC on hematoxylin and eosin (H&E) staining but could not be confirmed by Ulex europeaus agglutinin I lectin immunoperoxidase staining in 10. Forty-four MCs displayed a spray-like growth pattern, 34 a confluent pattern, and 12 both; one had a condylomatous appearance. Forty-eight MCs were grade 3, 27 were grade 2, and 16 were grade 1 in differentiation. Stromal response was assessed as absent in nine cases, weak in 53, moderate in 58, and intense in 80. The extent of associated cervical intraepithelial neoplasia (CIN) was widespread in all but nine cases. There were seven recurrences, including one definite and one possible tumor-related death. A single case of residual disease was observed. The new FIGO classification of preclinical stage Ia carcinoma as that diagnosed only by microscopy is sound. The division into stages Ia1 and Ia2 is reproducible and may be used for comparison between various institutions; the notion, however, that the length of MC should form part of its definition is not supported by these data. None of the variables (depth of invasion, length, area, volume, growth pattern, grade, stromal response, and CLSI) had any bearing on prognosis. Although stromal invasion can certainly be seen in small punch biopsies, a definitive diagnosis can be made only in conization (or hysterectomy) specimens. It is absolutely essential that conization specimens be thoroughly sampled, not only to make the correct diagnosis but also to be certain about the margins. Early stromal invasion behaves in the same manner as CIN and may be treated by conization alone provided the cone has been adequately sampled and the margins are free. Much the same applied to MC, although there were not enough patients whose tumors were associated with CLSI to be absolutely certain of the prognostic significance of the latter.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688352

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  5 in total

1.  Fourier transform infrared (FTIR) spectral mapping of the cervical transformation zone, and dysplastic squamous epithelium.

Authors:  B R Wood; L Chiriboga; H Yee; M A Quinn; D McNaughton; M Diem
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

2.  No association between polymorphisms of the DNA repair geneXRCC1 and cervical neoplasm risk.

Authors:  Ming-Tsang Wu; Shu-Yi Chen; Trong-Neng Wu; Hsing-Yu Hwang; Chi-Kung Ho; Li-Hung Lee; Su-Chu Wu
Journal:  Environ Health Prev Med       Date:  2003-07       Impact factor: 3.674

3.  Correlation of DNA ploidy with progression of cervical cancer.

Authors:  M Singh; S Mehrotra; N Kalra; U Singh; Y Shukla
Journal:  J Cancer Epidemiol       Date:  2008-01-29

4.  Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.

Authors:  Hanna-Mari Koskimaa; Anna E Paaso; Marij J P Welters; Seija E Grénman; Kari J Syrjänen; Sjoerd H van der Burg; Stina M Syrjänen
Journal:  J Transl Med       Date:  2014-02-13       Impact factor: 5.531

5.  Oncologic and obstetric outcomes after conization for adenocarcinoma in situ or stage IA1 cervical cancer.

Authors:  Xiaoyu Wang; Yalan Bi; Huanwen Wu; Ming Wu; Lei Li
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.